Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Explore how neutrophils shape the immune response in health and disease. This poster highlights neutrophil pathogen defense mechanisms, including phagocytosis, degranulation, and NETosis, as well as neutrophil roles in inflammation and NET-associated pathologies.
DOWNLOAD NOWCycloguanil is the active metabolite of the antimalarial prodrug proguanil.1 Cycloguanil is formed from proguanil by the cytochrome P450 (CYP) isoforms CYP2C19 and CYP3A in human liver microsomes. It is an inhibitor of dihydrofolate reductase (DHFR; Kis = 1.5 and 0.79 nM for the P. falciparum and P. berghei enzymes, respectively).2,3 It is active against ten P. falciparum field isolates (IC50s = 0.12-1,400 µg/ml).2 Cycloguanil reduces parasitemia in a mouse model of P. berghei infection (ED50 = 2 mg/kg).4 It also reduces parasitemia in a rhesus monkey model of P. cynomolgi infection when administered at a dose of 0.3 mg/kg.5
WARNING This product is not for human or veterinary use.
1. In vitro proguanil activation to cycloguanil by human liver microsomes is mediated by CYP3A isoforms as well as by S-
2. Amino acids in the dihydrofolate reductase-
3. Development of a lead inhibitor for the A16V+S108T mutant of dihydrofolate reductase from the cycloguanil-
4. The antimalarial activity of N-
5. Antimalarial activities of triazine metabolites of chlorguanide and dichlorguanide. Proc. Soc. Exp. Biol. Med. 80(2), 367-370 (1952).